Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free INMB Stock Alerts

INmune Bio (INMB) Financials

INmune Bio logo
$2.07 0.00 (0.00%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$2.07 0.00 (-0.05%)
As of 07/16/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for INmune Bio

Annual Income Statements for INmune Bio

This table shows INmune Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.83 -12 -7.68 -12 -30 -27 -30 -42 -46
Consolidated Net Income / (Loss)		 -0.83 -12 -7.68 -12 -30 -27 -30 -42 -46
Net Income / (Loss) Continuing Operations		 -0.98 -12 -7.68 -12 -30 -27 -30 -42 -46
Total Pre-Tax Income 		-0.98 -12 -7.68 -12 -30 -27 -30 -42 -46
Total Operating Income		 -0.98 -12 -7.76 -12 -29 -26 -30 -43 -47
Total Gross Profit		 0.00 0.00 0.00 0.01 0.18 0.37 0.16 0.01 0.05
Total Revenue		 0.00 0.00 0.00 0.01 0.18 0.37 0.16 0.01 0.05
Operating Revenue		 0.00 0.00 0.00 0.01 0.18 0.37 0.16 0.01 0.05
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 0.98 12 7.76 12 31 26 30 43 47
Selling, General & Admin Expense		 0.55 9.09 6.02 6.32 9.98 9.26 9.62 9.48 10
Research & Development Expense		 0.44 3.35 3.28 5.92 21 17 20 33 21
Impairment Charge		 - - - - - - - 0.00 17
Total Other Income / (Expense), net		 -0.00 0.00 0.08 0.13 0.00 -1.35 -0.27 0.55 1.45
Basic Earnings per Share		 ($0.13) ($1.43) ($0.75) ($1.01) ($1.88) ($1.52) ($1.67) ($2.11) ($1.86)
Weighted Average Basic Shares Outstanding		 6.56M 8.68M 10.27M 11.99M 16.13M 17.93M 17.98M 19.94M 24.76M
Diluted Earnings per Share		 ($0.13) ($1.43) ($0.75) ($1.01) - - ($1.67) ($2.11) ($1.86)
Weighted Average Diluted Shares Outstanding		 6.56M 8.68M 10.27M 11.99M 16.13M 17.95M 17.98M 19.94M 24.76M
Weighted Average Basic & Diluted Shares Outstanding		 6.56M 8.68M 10.27M 11.99M 16.13M 17.95M 18.03M - 26.59M

Quarterly Income Statements for INmune Bio

This table shows INmune Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.56 -8.41 -11 -9.75 -12 -9.22 -9.74 -24 -6.47 -5.26 -5.41
Consolidated Net Income / (Loss)		 -8.56 -8.41 -11 -9.75 -12 -9.22 -9.74 -24 -6.47 -5.26 -5.41
Net Income / (Loss) Continuing Operations		 -8.56 -8.41 -11 -9.75 -12 -9.23 -9.74 -24 -6.47 -5.26 -5.41
Total Pre-Tax Income 		-8.56 -8.41 -11 -9.75 -12 -9.23 -9.74 -24 -6.47 -5.26 -5.41
Total Operating Income		 -8.53 -8.38 -11 -9.87 -12 -9.47 -9.91 -25 -7.43 -5.47 -5.81
Total Gross Profit		 0.04 0.03 0.01 0.00 0.00 - 0.05 0.00 0.00 - 0.00
Total Revenue		 0.04 0.03 0.01 0.00 0.00 - 0.05 0.00 0.00 - 0.00
Operating Revenue		 0.04 0.03 0.01 0.00 0.00 - 0.05 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.57 8.41 11 9.87 12 9.46 9.96 25 7.43 5.47 5.81
Selling, General & Admin Expense		 2.59 2.40 2.34 2.81 2.22 2.11 2.32 2.25 2.55 3.15 2.17
Research & Development Expense		 5.99 6.01 8.69 7.05 10 7.35 7.64 5.80 4.89 2.33 3.64
Total Other Income / (Expense), net		 -0.04 -0.03 -0.01 0.12 0.19 0.24 0.17 0.11 0.96 0.21 0.41
Basic Earnings per Share		 ($0.48) ($0.47) ($0.61) ($0.50) ($0.60) ($0.40) ($0.43) ($1.05) ($0.24) ($0.14) ($0.20)
Weighted Average Basic Shares Outstanding		 18.01M 17.98M 18.03M 19.31M 20.19M 19.94M 22.50M 23.30M 26.59M 24.76M 26.59M
Diluted Earnings per Share		 ($0.48) - ($0.61) ($0.50) ($0.60) - ($0.43) ($1.05) ($0.24) ($0.14) ($0.20)
Weighted Average Diluted Shares Outstanding		 18.01M 17.98M 18.03M 19.31M 20.19M 19.94M 22.50M 23.30M 26.59M 24.76M 26.59M
Weighted Average Basic & Diluted Shares Outstanding		 18.02M 18.03M 19.78M 19.78M - 0.00 - - - 26.59M 26.59M

Annual Cash Flow Statements for INmune Bio

This table details how cash moves in and out of INmune Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.23 -1.18 6.81 15 53 -23 -16 -15 3.83
Net Cash From Operating Activities		 -0.76 -2.06 -5.38 -8.94 -29 -23 -12 -33 -23
Net Cash From Continuing Operating Activities		 -0.76 -2.06 -5.38 -8.94 -29 -23 -12 -33 -23
Net Income / (Loss) Continuing Operations		 -0.83 -12 -7.68 -12 -30 -27 -30 -42 -46
Consolidated Net Income / (Loss)		 -0.83 -12 -7.68 -12 -30 -27 -30 -42 -46
Depreciation Expense		 - - - - - - - 0.00 0.08
Amortization Expense		 - - - 0.00 0.13 0.24 0.22 0.08 0.00
Non-Cash Adjustments To Reconcile Net Income		 -0.02 10 2.52 3.17 4.80 6.54 7.26 7.72 26
Changes in Operating Assets and Liabilities, net		 0.08 0.13 -0.23 -0.01 -3.12 -2.86 11 0.92 -2.53
Net Cash From Investing Activities		 -0.10 0.00 0.00 0.00 -15 0.00 0.00 0.00 -1.04
Net Cash From Continuing Investing Activities		 -0.10 0.00 0.00 0.00 -15 0.00 0.00 0.00 -1.04
Purchase of Property, Plant & Equipment		 - - - - - - - 0.00 -1.04
Net Cash From Financing Activities		 2.06 0.90 12 24 96 0.73 -4.23 18 28
Net Cash From Continuing Financing Activities		 2.06 0.90 12 24 96 0.73 -4.23 18 28
Repayment of Debt		 - - - - - 0.00 -5.00 -10 0.00
Issuance of Common Equity		 2.06 0.90 12 25 - 0.70 0.78 28 28
Other Financing Activities, net		 - - 0.00 -1.01 81 0.03 0.00 0.42 0.07
Effect of Exchange Rate Changes		 0.03 -0.03 -0.02 0.02 - - - - -0.16
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.56 1.37 1.78 1.69 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for INmune Bio

This table details how cash moves in and out of INmune Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -6.01 -5.97 -9.85 5.07 2.48 -13 -1.59 14 -5.64 -2.98 -3.39
Net Cash From Operating Activities		 -4.26 -3.40 -7.48 -7.89 -6.99 -11 -6.82 -7.38 -5.44 -2.94 -3.40
Net Cash From Continuing Operating Activities		 -4.26 -3.40 -7.48 -7.89 -6.99 -11 -6.82 -7.38 -5.44 -2.94 -3.40
Net Income / (Loss) Continuing Operations		 -8.56 -8.41 -11 -9.75 -12 -9.22 -9.74 -24 -6.47 -5.26 -5.41
Consolidated Net Income / (Loss)		 -8.56 -8.41 -11 -9.75 -12 -9.22 -9.74 -24 -6.47 -5.26 -5.41
Depreciation Expense		 - - - - - - 0.00 - - 0.06 0.05
Non-Cash Adjustments To Reconcile Net Income		 1.92 1.75 1.89 2.37 1.70 1.77 2.08 18 2.30 3.38 1.39
Changes in Operating Assets and Liabilities, net		 2.33 3.22 1.62 -0.53 3.39 -3.57 0.84 -0.97 -1.29 -1.11 0.57
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 -0.71 -0.19 -0.14 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 -0.71 -0.19 -0.14 0.00
Net Cash From Financing Activities		 -1.73 -2.50 -2.50 13 9.79 -2.08 5.27 22 - 0.07 0.00
Net Cash From Continuing Financing Activities		 -1.73 -2.50 -2.50 13 9.79 -2.08 5.27 22 - 0.07 0.00
Issuance of Common Equity		 0.78 - 0.00 15 12 - 5.27 22 - - 0.00
Other Financing Activities, net		 - - 0.00 - - - 0.00 - - 0.07 0.00
Other Net Changes in Cash		 -0.02 -0.06 0.13 -0.04 -0.32 0.46 - -0.15 -0.01 - 0.01
Cash Interest Paid		 0.46 0.38 0.30 0.22 0.14 1.03 0.00 - - - 0.00
Cash Income Taxes Paid		 - - 0.00 - - - 0.00 - - - 0.00

Annual Balance Sheets for INmune Bio

This table presents INmune Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 18 17 24 41 100 82 57 40 32
Total Current Assets		 1.90 0.85 7.76 24 83 65 40 23 30
Cash & Equivalents		 1.37 0.19 7.00 22 75 52 36 21 25
Accounts Receivable		 - - - - - 0.36 2.44 1.41 4.54
Prepaid Expenses		 0.20 0.02 0.12 0.22 2.29 4.06 1.65 0.33 0.60
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.96
Total Noncurrent Assets		 17 17 17 17 17 17 17 17 1.51
Other Noncurrent Operating Assets		 - 0.00 0.19 0.16 0.83 0.61 0.55 0.39 1.51
Total Liabilities & Shareholders' Equity		 18 17 24 41 100 82 57 40 32
Total Liabilities		 0.31 0.82 0.86 1.90 20 22 19 7.47 8.83
Total Current Liabilities		 0.31 0.82 0.70 1.78 4.36 11 18 7.22 8.42
Accounts Payable		 0.31 0.82 0.69 1.55 3.81 5.21 7.90 6.56 7.79
Other Current Liabilities		 - 0.00 0.01 0.22 0.55 0.70 0.61 0.66 0.62
Total Noncurrent Liabilities		 0.00 0.00 0.16 0.13 15 11 0.40 0.24 0.41
Other Noncurrent Operating Liabilities		 - 0.00 0.16 0.13 0.90 0.55 0.40 0.24 0.41
Total Equity & Noncontrolling Interests		 18 17 24 39 80 60 37 32 24
Total Preferred & Common Equity		 18 17 24 39 80 60 37 32 24
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Common Equity		 18 17 24 39 80 60 37 32 24
Common Stock		 19 25 45 72 144 152 159 196 233
Retained Earnings		 -1.16 -14 -21 -33 -64 -91 -121 -163 -209
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.01 -0.01 0.01 0.00 -0.70 -0.80 -0.58 -0.74
Other Equity Adjustments		 0.05 4.68 0.05 - - - - 0.00 0.00

Quarterly Balance Sheets for INmune Bio

This table presents INmune Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 63 47 52 53 38 38 33 26
Total Current Assets		 46 30 35 36 21 36 31 23
Cash & Equivalents		 42 26 31 34 19 33 28 21
Accounts Receivable		 - 0.56 3.41 1.42 1.42 2.16 2.46 0.77
Prepaid Expenses		 1.54 1.13 1.01 0.88 0.21 0.51 0.47 0.69
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.71 0.88 0.90
Total Noncurrent Assets		 17 17 17 17 17 0.94 1.81 2.09
Other Noncurrent Operating Assets		 0.57 0.50 0.44 0.42 0.33 0.94 1.81 2.09
Total Liabilities & Shareholders' Equity		 63 47 52 53 38 38 33 26
Total Liabilities		 18 18 15 14 8.13 8.82 7.98 6.19
Total Current Liabilities		 14 17 15 14 7.93 8.59 7.36 5.39
Accounts Payable		 3.68 9.29 9.28 11 7.30 7.86 6.90 4.68
Other Current Liabilities		 0.60 0.65 0.65 0.68 0.63 0.73 0.46 0.70
Total Noncurrent Liabilities		 3.61 0.36 0.32 0.28 0.20 0.23 0.62 0.81
Other Noncurrent Operating Liabilities		 0.80 - - 0.28 - - - 0.81
Total Equity & Noncontrolling Interests		 44 28 36 39 30 29 25 20
Total Preferred & Common Equity		 44 28 36 39 30 29 25 20
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 44 28 36 39 30 29 25 20
Common Stock		 157 161 179 194 203 227 230 235
Retained Earnings		 -113 -132 -142 -154 -173 -197 -204 -214
Accumulated Other Comprehensive Income / (Loss)		 -0.74 -0.67 -0.71 -1.04 -0.61 -0.76 -0.76 -0.73
Other Equity Adjustments		 - - - - - - - 0.00

Annual Metrics And Ratios for INmune Bio

This table displays calculated financial ratios and metrics derived from INmune Bio's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 10,770,948.00 13,447,948.00 17,843,303.00 17,945,995.00 18,021,692.00 - 18,021,692.00
DEI Adjusted Shares Outstanding		 0.00 0.00 10,770,948.00 13,447,948.00 17,843,303.00 17,945,995.00 18,021,692.00 - 18,021,692.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.71 -0.90 -1.70 -1.52 -1.67 - -2.55
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 1,545.45% 106.63% -58.56% -90.97% 257.14%
EBITDA Growth		 0.00% -1,167.47% 38.28% -57.57% -139.91% 6.78% -10.07% -41.03% -11.15%
EBIT Growth		 0.00% -1,167.47% 38.28% -57.57% -140.95% 6.36% -9.92% -40.24% -11.14%
NOPAT Growth		 0.00% -1,167.48% 37.65% -57.66% -138.41% 10.98% -14.60% -43.35% -11.14%
Net Income Growth		 0.00% -1,396.12% 38.28% -57.57% -150.76% 10.02% -9.92% -40.24% -9.15%
EPS Growth		 0.00% -1,000.00% 47.55% -34.67% 0.00% 0.00% 0.00% -26.35% 11.85%
Operating Cash Flow Growth		 0.00% -170.27% -161.52% -66.08% -218.73% 20.41% 47.19% -178.47% 32.31%
Free Cash Flow Firm Growth		 0.00% 0.00% 31.68% -53.47% -169.04% 8.63% 53.92% -190.88% 27.83%
Invested Capital Growth		 0.00% -2.27% 1.60% 1.04% 18.38% 16.61% -47.15% -8.75% -110.98%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 524.14% -15.00% -30.80% -66.67% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -5.13% -6.59% -24.78% 7.05% -11.31% -1.39% 7.92%
EBIT Q/Q Growth		 0.00% 0.00% -5.13% -6.59% -24.95% 6.95% -11.12% -1.29% 7.77%
NOPAT Q/Q Growth		 0.00% 0.00% -6.19% -7.72% -24.95% 11.55% -10.14% -2.62% 7.77%
Net Income Q/Q Growth		 0.00% 0.00% -6.05% -7.90% -27.09% 12.33% -9.39% -1.96% 7.93%
EPS Q/Q Growth		 0.00% 0.00% -2.74% -3.06% 0.00% 0.00% 0.00% 0.00% 12.26%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.54% -28.04% -34.99% 15.26% 16.07% -29.56% 26.33%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -16.21% -33.31% 7.80% 27.79% -36.82% 21.81%
Invested Capital Q/Q Growth		 0.00% 0.00% -4.11% -0.64% 9.28% 10.72% -22.12% 45.66% 29.20%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% -109,990.91% -16,037.02% -7,235.29% -19,215.48% -300,021.43% -94,598.00%
Operating Margin		 0.00% 0.00% 0.00% -111,163.64% -16,106.63% -6,938.77% -19,187.74% -304,535.71% -94,766.00%
EBIT Margin		 0.00% 0.00% 0.00% -109,990.91% -16,106.63% -7,299.20% -19,360.00% -300,585.71% -94,766.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -109,990.91% -16,762.43% -7,299.20% -19,360.00% -300,585.71% -91,866.00%
Tax Burden Percent		 84.72% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 104.07% 100.00% 100.00% 100.00% 96.94%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -51.25% -111.33% -84.40% -117.55% -254.84% -666.83%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -26.81% -87.20% -65.62% -88.30% -202.56% -610.93%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 12.45% 60.33% 45.49% 56.46% 135.01% 501.67%
Return on Equity (ROE)		 -4.59% -71.82% -38.25% -38.80% -51.00% -38.91% -61.09% -119.83% -165.16%
Cash Return on Invested Capital (CROIC)		 0.00% -50.34% -34.52% -52.29% -128.17% -99.74% -55.85% -245.69% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -37.16% -41.47% -30.04% -43.24% -87.16% -131.78%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -37.16% -43.16% -30.04% -43.24% -87.16% -127.75%
Return on Common Equity (ROCE)		 -4.59% -71.82% -38.25% -38.80% -51.00% -38.91% -60.59% -118.47% -165.16%
Return on Equity Simple (ROE_SIMPLE)		 -4.59% -75.21% -32.52% -31.22% -37.82% -45.42% -80.36% -131.11% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.69 -8.71 -5.43 -8.56 -20 -18 -21 -30 -33
NOPAT Margin		 0.00% 0.00% 0.00% -77,814.55% -11,274.64% -4,857.14% -13,431.42% -213,175.00% -66,336.20%
Net Nonoperating Expense Percent (NNEP)		 -10.54% -479.41% -62.63% -24.44% -24.13% -18.78% -29.26% -52.28% -55.90%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -44.05% -92.98% -141.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 57,463.64% 5,512.71% 2,475.40% 6,208.39% 67,735.71% 20,520.00%
R&D to Revenue		 0.00% 0.00% 0.00% 53,800.00% 11,349.72% 4,563.37% 13,079.35% 236,900.00% 41,318.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 111,263.64% 16,862.43% 7,038.77% 19,287.74% 304,635.71% 94,866.00%
Earnings before Interest and Taxes (EBIT)		 -0.98 -12 -7.68 -12 -29 -27 -30 -42 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.98 -12 -7.68 -12 -29 -27 -30 -42 -47
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.45 0.49 2.52 5.33 2.05 1.89 5.42 2.90 1.64
Price to Tangible Book Value (P/TBV)		 5.14 319.22 8.40 9.28 2.58 2.61 9.72 5.98 1.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 18,767.44 909.01 304.22 1,306.22 6,652.85 772.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.41 0.49 3.17 10.99 5.24 3.32 14.48 6.46 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 16,770.44 575.58 205.47 1,144.10 5,158.42 277.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.18 0.25 0.26 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.18 0.17 0.00 0.00 0.00
Financial Leverage		 -0.08 -0.04 -0.18 -0.46 -0.69 -0.69 -0.64 -0.67 -0.82
Leverage Ratio		 1.02 1.03 1.04 1.04 1.18 1.30 1.41 1.37 1.29
Compound Leverage Factor		 1.02 1.03 1.04 1.04 1.23 1.30 1.41 1.37 1.25
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 15.27% 20.21% 20.64% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 6.64% 20.64% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 15.27% 13.57% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.66% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 84.73% 79.79% 77.69% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.50 -0.56 -0.33 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 2.08 1.36 0.87 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.50 -0.38 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.71 -0.84 -0.48 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 2.96 2.03 1.25 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.71 -0.56 0.00 0.00 0.00
Altman Z-Score		 15.66 2.49 39.64 63.65 4.09 1.28 2.19 -1.33 -10.46
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.81% 1.14% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 6.13 1.03 11.09 13.51 18.95 5.92 2.16 3.14 3.55
Quick Ratio		 4.43 0.23 9.99 12.37 17.16 4.81 2.07 3.09 3.48
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.33 -5.69 -8.73 -23 -21 -9.89 -29 -21
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,167.18%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.01 0.02
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 3,301.48 50,200.54 21,717.50
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 3,301.48 50,200.54 21,717.50
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 17 16 17 17 20 23 12 11 -1.23
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.00 0.01
Increase / (Decrease) in Invested Capital		 0.00 -0.38 0.26 0.17 3.09 3.30 -11 -1.07 -12
Enterprise Value (EV)		 6.79 7.98 53 184 104 77 177 72 14
Market Capitalization		 8.16 8.16 60 206 165 114 202 93 39
Book Value per Share		 $2.76 $1.91 $2.19 $2.88 $4.50 $3.35 $2.07 $1.61 $0.95
Tangible Book Value per Share		 $0.24 $0.00 $0.66 $1.65 $3.57 $2.43 $1.16 $0.78 $0.95
Total Capital		 18 17 24 39 95 75 48 32 24
Total Debt		 0.00 0.00 0.00 0.00 14 15 9.92 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 14 10 0.00 0.00 0.00
Net Debt		 -1.37 -0.19 -7.00 -22 -60 -37 -26 -21 -25
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.22 -0.16 0.07 0.24 3.44 6.60 -4.45 -5.48 -3.28
Debt-free Net Working Capital (DFNWC)		 1.59 0.03 7.06 22 78 59 31 15 21
Net Working Capital (NWC)		 1.59 0.03 7.06 22 78 54 21 15 21
Net Nonoperating Expense (NNE)		 0.14 3.73 2.25 3.54 9.93 9.13 9.19 12 13
Net Nonoperating Obligations (NNO)		 -1.37 -0.19 -7.00 -22 -60 -37 -26 -21 -25
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.13 0.24 0.22 0.08 0.08
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 2,209.09% 1,898.90% 1,765.78% -2,870.97% -39,150.00% -6,560.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 201,909.09% 43,230.39% 15,710.43% 20,256.77% 110,292.86% 42,942.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 201,909.09% 43,230.39% 14,373.53% 13,856.13% 110,292.86% 42,942.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.13) ($1.43) ($0.75) ($1.01) ($1.88) ($1.52) ($1.67) ($2.11) ($1.86)
Adjusted Weighted Average Basic Shares Outstanding		 6.56M 9.74M 10.75M 14.93M 17.86M 17.93M 17.98M 19.94M 24.76M
Adjusted Diluted Earnings per Share		 ($0.13) ($1.43) ($0.75) ($1.01) ($1.88) $0.00 $0.00 ($2.11) ($1.86)
Adjusted Weighted Average Diluted Shares Outstanding		 6.56M 9.74M 10.75M 14.93M 17.86M 17.95M 18.03M 19.94M 24.76M
Adjusted Basic & Diluted Earnings per Share		 ($0.13) ($1.43) ($0.75) ($1.01) ($1.88) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.56M 8.68M 10.27M 11.99M 16.13M 17.95M 18.03M 0.00 26.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.69 -8.71 -5.43 -8.56 -20 -18 -21 -30 -22
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -77,814.55% -11,274.64% -4,857.14% -13,431.42% -213,175.00% -43,216.60%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -109,990.91% -16,762.43% -7,299.20% -19,360.00% -300,585.71% -91,866.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for INmune Bio

This table displays calculated financial ratios and metrics derived from INmune Bio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 18,021,692.00 18,021,692.00 18,021,692.00 18,021,692.00 18,021,692.00 - 18,021,692.00 18,021,692.00 18,021,692.00 18,021,692.00 26,585,258.00
DEI Adjusted Shares Outstanding		 18,021,692.00 18,021,692.00 18,021,692.00 18,021,692.00 18,021,692.00 - 18,021,692.00 18,021,692.00 18,021,692.00 18,021,692.00 26,585,258.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.48 -0.47 -0.61 -0.54 -0.67 - -0.54 -1.36 -0.36 -0.29 -0.20
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -56.12% -71.13% -63.16% -100.00% -100.00% 0.00% 257.14% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 -10.53% -49.52% -69.90% -52.74% -44.81% -13.52% 9.88% -149.68% 39.43% 42.73% 41.85%
EBIT Growth		 -10.39% -48.51% -68.68% -51.75% -44.07% -12.98% 10.16% -149.07% 39.50% 42.18% 41.32%
NOPAT Growth		 -14.58% -48.51% -71.52% -53.88% -44.07% -12.98% 10.09% -149.07% 39.50% 42.18% 41.32%
Net Income Growth		 -10.85% -44.15% -68.68% -49.92% -41.22% -9.63% 11.66% -150.95% 46.48% 42.89% 44.48%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -25.00% 0.00% 29.51% -110.00% 60.00% 65.00% 53.49%
Operating Cash Flow Growth		 -26.64% 40.28% -555.21% -148.46% -63.84% -223.82% 8.72% 6.48% 22.14% 73.27% 50.13%
Free Cash Flow Firm Growth		 90.39% 169.81% 503.73% -149.16% 28.43% -209.74% -1,403.18% -184.50% 867.89% 254.28% 223.64%
Invested Capital Growth		 -24.87% -47.15% -43.14% -35.91% -51.21% -8.75% -2.76% -137.80% -122.59% -110.98% -116.46%
Revenue Q/Q Growth		 -6.52% -34.88% -50.00% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -31.52% 1.65% -31.88% 10.46% -24.69% 22.90% -4.69% -152.29% 69.75% 27.11% -6.31%
EBIT Q/Q Growth		 -31.18% 1.75% -31.58% 10.52% -24.54% 22.94% -4.63% -152.29% 69.75% 26.36% -6.17%
NOPAT Q/Q Growth		 -33.02% 1.75% -31.48% 10.46% -24.54% 22.94% -4.63% -148.07% 69.75% 26.36% -6.17%
Net Income Q/Q Growth		 -31.72% 1.81% -31.13% 11.60% -24.08% 23.77% -5.65% -151.13% 73.54% 18.67% -2.72%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 18.03% -20.00% 0.00% -7.50% -144.19% 77.14% 41.67% -42.86%
Operating Cash Flow Q/Q Growth		 -34.34% 20.24% -119.82% -5.48% 11.41% -57.64% 38.04% -8.07% 26.25% 45.87% -15.59%
Free Cash Flow Firm Q/Q Growth		 -166.35% 762.01% -89.94% -211.27% 3.41% -915.15% -19.44% 75.71% 360.71% 103.96% -4.29%
Invested Capital Q/Q Growth		 -10.91% -22.12% -11.52% 4.39% -32.18% 45.66% -5.71% -140.58% 59.47% 29.20% -41.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -19,706.98% -29,764.29% -78,507.14% 0.00% 0.00% 0.00% -19,810.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -19,832.56% -29,925.00% -78,692.86% 0.00% 0.00% 0.00% -19,810.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -19,832.56% -29,925.00% -78,750.00% 0.00% 0.00% 0.00% -19,810.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -19,913.95% -30,028.57% -78,750.00% 0.00% 0.00% 0.00% -19,478.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 99.91% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.41% 100.35% 100.00% 98.79% 98.43% 97.45% 98.32% 99.54% 87.07% 96.16% 93.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -169.68% -183.33% -482.80% 0.00% 0.00% 0.00% -64.88% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -162.45% -175.23% -470.62% 0.00% 0.00% 0.00% -49.85% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 107.54% 112.05% 303.78% 0.00% 0.00% 0.00% 31.70% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -62.14% -71.28% -179.02% 0.00% 0.00% 0.00% -33.18% 0.00% 0.00% 0.00% -168.78%
Cash Return on Invested Capital (CROIC)		 -74.74% -55.85% -105.80% -138.89% -179.77% -245.69% -269.19% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -60.65% -66.84% -170.78% 0.00% 0.00% 0.00% -23.41% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -60.90% -67.07% -170.78% 0.00% 0.00% 0.00% -23.01% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -61.68% -70.70% -177.32% 0.00% 0.00% 0.00% -32.73% 0.00% 0.00% 0.00% -168.78%
Return on Equity Simple (ROE_SIMPLE)		 -62.44% 0.00% -122.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.97 -5.87 -7.71 -6.91 -8.60 -6.63 -6.93 -17 -5.20 -3.83 -4.07
NOPAT Margin		 -13,882.79% -20,947.50% -55,085.00% 0.00% 0.00% 0.00% -13,867.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.23% -8.09% -12.17% -9.67% -11.64% -11.07% -15.03% -24.64% -4.37% -6.27% -6.61%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.41% -21.40% -16.61% -20.89% -20.65% -23.21% -59.11% -20.01% -16.29% -20.73%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 6,013.95% 8,571.43% 16,700.00% 0.00% 0.00% 0.00% 4,632.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 13,918.60% 21,453.57% 62,092.86% 0.00% 0.00% 0.00% 15,278.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 19,932.56% 30,025.00% 78,792.86% 0.00% 0.00% 0.00% 19,910.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.53 -8.38 -11 -9.87 -12 -9.47 -9.91 -25 -7.43 -5.47 -5.81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.47 -8.33 -11 -9.84 -12 -9.46 -9.91 -25 -7.43 -5.42 -5.76
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.78 5.42 7.50 4.69 2.81 2.90 5.92 1.86 2.17 1.64 1.53
Price to Tangible Book Value (P/TBV)		 4.45 9.72 18.09 8.61 4.91 5.98 13.35 1.86 2.17 1.64 1.53
Price to Revenue (P/Rev)		 544.27 1,306.22 1,616.88 2,003.42 2,590.50 6,652.85 3,513.91 1,076.39 1,100.63 772.44 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.96 14.48 17.94 12.85 10.13 6.46 14.86 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 418.34 1,144.10 1,484.15 1,709.67 1,851.02 5,158.42 3,131.19 413.53 558.41 277.42 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.29 0.26 0.27 0.14 0.06 0.00 0.01 0.01 0.02 0.00 0.00
Long-Term Debt to Equity		 0.06 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.02 0.00 0.00
Financial Leverage		 -0.66 -0.64 -0.65 -0.67 -0.72 -0.67 -0.64 -0.89 -0.91 -0.82 -0.82
Leverage Ratio		 1.35 1.41 1.43 1.39 1.38 1.37 1.44 1.37 1.34 1.29 1.29
Compound Leverage Factor		 1.36 1.42 1.43 1.38 1.36 1.34 1.42 1.36 1.17 1.24 1.20
Debt to Total Capital		 22.26% 20.64% 21.21% 12.51% 6.06% 0.00% 0.67% 0.79% 2.40% 0.00% 0.00%
Short-Term Debt to Total Capital		 17.38% 20.64% 20.24% 11.75% 6.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 4.88% 0.00% 0.98% 0.76% 0.00% 0.00% 0.67% 0.79% 2.40% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1.39% 1.66% 2.17% 1.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 76.35% 77.69% 76.62% 85.61% 93.94% 100.00% 99.33% 99.21% 97.60% 100.00% 100.00%
Debt to EBITDA		 -0.48 -0.33 -0.23 -0.14 -0.06 0.00 0.00 0.00 -0.01 0.00 0.00
Net Debt to EBITDA		 1.08 0.87 0.53 0.68 0.75 0.00 0.46 0.59 0.53 0.00 0.00
Long-Term Debt to EBITDA		 -0.10 0.00 -0.01 -0.01 0.00 0.00 0.00 0.00 -0.01 0.00 0.00
Debt to NOPAT		 -0.68 -0.48 -0.33 -0.20 -0.09 0.00 -0.01 -0.01 -0.02 0.00 0.00
Net Debt to NOPAT		 1.53 1.25 0.76 0.97 1.07 0.00 0.66 0.84 0.75 0.00 0.00
Long-Term Debt to NOPAT		 -0.15 0.00 -0.02 -0.01 0.00 0.00 -0.01 -0.01 -0.02 0.00 0.00
Altman Z-Score		 1.71 3.44 2.73 2.71 0.28 1.39 6.12 -4.94 -4.31 -6.18 -8.65
Noncontrolling Interest Sharing Ratio		 0.74% 0.81% 0.95% 0.00% 0.00% 0.00% 1.36% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.18 2.16 1.71 2.36 2.59 3.14 2.64 4.20 4.17 3.55 4.24
Quick Ratio		 2.91 2.07 1.52 2.29 2.53 3.09 2.62 4.14 4.10 3.48 4.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.76 5.06 0.51 -0.57 -0.55 -5.55 -6.63 -1.61 4.20 8.57 8.20
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,818.13% -2,058.74% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.11 0.00 0.00 0.00 0.01 0.05 0.02 0.03 0.02 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 3,301.48 0.00 0.00 0.00 50,200.54 7,201.45 20,323.20 14,176.60 21,717.50 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 3,301.48 0.00 0.00 0.00 50,200.54 7,201.45 20,323.20 14,176.60 21,717.50 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 16 12 11 11 7.67 11 11 -4.28 -1.73 -1.23 -1.73
Invested Capital Turnover		 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.00
Increase / (Decrease) in Invested Capital		 -5.21 -11 -8.22 -6.34 -8.05 -1.07 -0.30 -16 -9.41 -12 -12
Enterprise Value (EV)		 94 177 194 145 78 72 157 21 28 14 8.68
Market Capitalization		 122 202 212 170 109 93 176 54 55 39 30
Book Value per Share		 $2.44 $2.07 $1.57 $1.88 $1.92 $1.61 $1.32 $1.24 $0.95 $0.95 $0.74
Tangible Book Value per Share		 $1.52 $1.16 $0.65 $1.02 $1.10 $0.78 $0.58 $1.24 $0.95 $0.95 $0.74
Total Capital		 58 48 37 42 41 32 30 29 26 24 20
Total Debt		 13 9.92 7.82 5.30 2.49 0.00 0.20 0.23 0.62 0.00 0.00
Total Long-Term Debt		 2.81 0.00 0.36 0.32 0.00 0.00 0.20 0.23 0.62 0.00 0.00
Net Debt		 -29 -26 -18 -26 -31 -21 -19 -33 -27 -25 -21
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.14 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.56 -4.45 -6.17 -5.65 -9.03 -5.48 -6.30 -5.93 -4.42 -3.28 -3.92
Debt-free Net Working Capital (DFNWC)		 41 31 20 25 25 15 13 27 23 21 17
Net Working Capital (NWC)		 31 21 12 20 22 15 13 27 23 21 17
Net Nonoperating Expense (NNE)		 2.59 2.54 3.31 2.84 3.49 2.59 2.81 7.26 1.27 1.43 1.34
Net Nonoperating Obligations (NNO)		 -29 -26 -18 -26 -31 -21 -19 -33 -27 -25 -21
Total Depreciation and Amortization (D&A)		 0.05 0.05 0.03 0.02 0.02 0.01 0.00 0.00 0.00 0.06 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 -249.11% -2,870.97% -4,712.21% -6,642.35% -21,500.00% -39,150.00% -12,608.00% -11,852.00% -8,842.00% -6,560.00% 0.00%
Debt-free Net Working Capital to Revenue		 18,417.41% 20,256.77% 15,136.64% 29,909.41% 58,385.71% 110,292.86% 26,066.00% 54,896.00% 46,626.00% 42,942.00% 0.00%
Net Working Capital to Revenue		 13,953.13% 13,856.13% 9,445.80% 24,051.76% 52,447.62% 110,292.86% 26,066.00% 54,896.00% 46,626.00% 42,942.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.48) ($0.47) ($0.61) ($0.50) ($0.60) ($0.40) ($0.43) ($1.05) ($0.24) ($0.14) ($0.20)
Adjusted Weighted Average Basic Shares Outstanding		 18.01M 17.98M 18.03M 19.31M 20.19M 19.94M 22.50M 23.30M 26.59M 24.76M 26.59M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.60) $0.00 ($0.43) ($1.05) ($0.24) ($0.14) ($0.20)
Adjusted Weighted Average Diluted Shares Outstanding		 18.02M 17.98M 19.78M 19.78M 20.19M 19.94M 22.50M 23.30M 26.59M 24.76M 26.59M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 18.02M 18.03M 19.78M 19.78M 0.00 0.00 0.00 0.00 0.00 26.59M 26.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.97 -5.87 -7.71 -6.91 -8.60 -6.63 -6.93 -5.64 -5.20 -3.83 -4.07
Normalized NOPAT Margin		 -13,882.79% -20,947.50% -55,085.00% 0.00% 0.00% 0.00% -13,867.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -19,913.95% -30,028.57% -78,750.00% 0.00% 0.00% 0.00% -19,478.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

INmune Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, INmune Bio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

INmune Bio's net income appears to be on an upward trend, with a most recent value of -$45.93 million in 2025, rising from -$831.49 thousand in 2017. The previous period was -$42.08 million in 2024. Check out INmune Bio's forecast to explore projected trends and price targets.

INmune Bio's total operating income in 2025 was -$47.38 million, based on the following breakdown:
  • Total Gross Profit: $50 thousand
  • Total Operating Expenses: $47.43 million

Over the last 8 years, INmune Bio's total revenue changed from $0.00 in 2017 to $50 thousand in 2025, a change of 5,000,000.0%.

INmune Bio's total liabilities were at $8.83 million at the end of 2025, a 18.2% increase from 2024, and a 2,750.0% increase since 2017.

In the past 8 years, INmune Bio's cash and equivalents has ranged from $186.20 thousand in 2018 to $74.81 million in 2021, and is currently $24.75 million as of their latest financial filing in 2025.

Over the last 8 years, INmune Bio's book value per share changed from 2.76 in 2017 to 0.95 in 2025, a change of -65.5%.


Related Companies

Financial statements for NASDAQ:INMB last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel